© Rosalind Scientific LLC 2018-2022
New Drug Hunter content, featured events and job postings straight to your inbox. Trusted by >4,000 drug hunters worldwide, unsubscribe anytime.
Home > CC-90011
<< Back to October
selective, reversible LSD1 inhibitor
<100 mg orally QW, in Ph. II for 1L ES-SCLC
from 300k+ cmpd HTS, SBDD + opt.
J. Med. Chem., Oct. 9, 2020
Celgene/Bristol Myers Squibb, San Diego, CA
CC-90011 (Celgene/Bristol Myers Squibb (BMS)) selective, reversible LSD1 inhibitor clinical candidate)
Unlock this content with a Premium membership to read it now.